PURPOSE: To determine the response, failure-free survival (FFS), and overall survival rates and @entity137 of rituximab plus an intense chemotherapy regimen in @entity1 with previously untreated aggressive @entity1073 ( @entity1073 ). @entity1 AND METHODS: This was a prospective phase II trial of rituximab plus fractionated @entity786 , @entity1891 , @entity632 , and @entity619 ( @entity2915 ; considered one cycle) alternating every 21 days with rituximab plus high-dose @entity1499 - @entity2592 (considered one cycle) for a total of six to eight cycles. RESULTS: Of 97 assessable @entity1 , 97% responded, and 87% achieved a complete response (CR) or unconfirmed CR. With a median follow-up time of 40 months, the 3-year FFS and overall survival rates were 64% and 82%, respectively, without a plateau in the curves. For the subgroup of @entity1 < or = 65 years of age, the 3-year FFS rate was 73%. The principal @entity137 was hematologic. Five @entity1 died from acute @entity137 . Four @entity1 developed treatment-related @entity2590 / @entity3052 , and three @entity1 died while in remission from @entity1073 . A total of eight treatment-related @entity204 (8%) occurred. CONCLUSION: Rituximab plus @entity2915 alternating with rituximab plus high-dose @entity1499 and @entity2592 is effective in untreated aggressive @entity1073 . @entity137 is significant but expected. Because of the shorter FFS concurrent with significant @entity137 in @entity1 more than 65 years of age, this regimen is not recommended as standard therapy for this age subgroup. Larger prospective randomized studies are needed to define the role of this regimen in the treatment of @entity1073 @entity1 compared with existing and new treatment modalities.

High rate of durable remissions after treatment of newly diagnosed aggressive @entity1073 with rituximab plus @entity2915 alternating with rituximab plus high-dose @entity1499 and XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'Toxicity'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity2590 :: ('MESH:D009190', 'Disease') :: ['myelodysplasia'] @entity2592 :: ('MESH:D003561', 'Chemical') :: ['cytarabine'] @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute myelogenous leukemia'] @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone'] @entity2915 :: ('MESH:D006948', 'Disease') :: ['hyper-CVAD'] @entity1891 :: ('MESH:D014750', 'Chemical') :: ['vincristine'] @entity1073 :: ('MESH:D020522', 'Disease') :: ['mantle-cell lymphoma', 'MCL'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate'] @entity204 :: ('MESH:D003643', 'Disease') :: ['deaths']
@entity2592 :: (MESH:D003561,Chemical) :: ['cytarabine']
